13F filer · CIK 2005245
Siren, L.L.C.
New York, NY · filing since Q3 2024 · last filing Aug 13, 2026
Reported value
$4.9B
+$1.3B vs prior
Positions
117
New / sold out
27 / 10
Added / reduced
31 / 21
Turnover
11.0%
buys $824.1M · sells $469.7M
Top-10 weight
44.6%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Parabilis Medicines Inc | +2,992,259 | – | +$81.9M |
| New | Abivax SA | +576,000 | – | +$76.8M |
| New | Hemab Therapeutics Holdings Inc | +2,086,834 | – | +$76.6M |
| New | Relay Therapeutics Inc | +3,650,000 | – | +$68.3M |
| Added | Enliven Therapeutics Inc | +1,028,185 | +137.8% | +$52.2M |
| New | Kailera Therapeutics Inc | +2,214,286 | – | +$48.8M |
| Added | Rhythm Pharmaceuticals Inc | +410,764 | +56.6% | +$45.6M |
| New | Capital One Finl Corp | +171,615 | – | +$34.4M |
| New | Oruka Therapeutics Inc | +250,000 | – | +$23.8M |
| New | Seaport Therapeutics Inc | +1,095,316 | – | +$23.8M |
48 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | Scholar Rock Holding Corp | -1,250,000 | -11.5% | $-68.8M |
| Reduced | Edgewise Therapeutics Inc | -1,245,634 | -28.1% | $-50.6M |
| Sold out | Centessa Pharmaceuticals PLC | -1,053,464 | -100.0% | $-41.8M |
| Reduced | Revolution Medicines Inc | -210,980 | -19.0% | $-39.5M |
| Sold out | enGene Holdings Inc | -5,253,159 | -100.0% | $-35.8M |
| Reduced | Kymera Therapeutics Inc | -251,000 | -7.9% | $-28.8M |
| Reduced | Structure Therapeutics Inc | -455,731 | -34.3% | $-24.5M |
| Reduced | Arcus Biosciences Inc | -586,647 | -19.5% | $-18.1M |
| Reduced | Crinetics Pharmaceuticals Inc | -482,848 | -25.4% | $-18.1M |
| Sold out | Fulcrum Therapeutics Inc | -2,350,000 | -100.0% | $-18.0M |
21 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Scholar Rock Holding CorpCOM | 9,575,013 | $526.6M | 10.66% |
| 2 | Kymera Therapeutics IncCOM | 2,935,830 | $336.7M | 6.81% |
| 3 | Erasca IncCOM | 11,397,781 | $208.8M | 4.23% |
| 4 | Veradermics IncCOMMON STOCK | 1,655,374 | $203.5M | 4.12% |
| 5 | Tango Therapeutics IncCOM | 6,179,364 | $193.2M | 3.91% |
| 6 | Revolution Medicines IncCOM | 900,000 | $168.6M | 3.41% |
| 7 | Bicara Therapeutics IncCOM | 5,602,970 | $166.4M | 3.37% |
| 8 | Arrowhead Pharmaceuticals IncCOM | 1,715,476 | $139.8M | 2.83% |
| 9 | BeOne Medicines AGSPONSORED ADS | 465,000 | $132.5M | 2.68% |
| 10 | Edgewise Therapeutics IncCOM | 3,184,629 | $129.4M | 2.62% |
107 more rows. Subscribe for $29/month to see every row, download the data and use the API.